Sarepta Therapeutics (SRPT) Says USPTO Issued Favorable Decisions on Exon 51 and Exon 53 Composition in Case vs BioMarin (BMRN)

Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical

Final refusal of BioMarins interfering claims facilitates commercialization of EXONDYS 51 (eteplirsen) in US Key patent protection for EXONDYS 51 and SRP-4053 remains valid

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued two favorable decisions for Sarepta in the composition of matter patent interferences for exon 51 (Interference No. 106,008) and exon 53 (Interference No. 106,007). These decisions,... More